Risk of Subsequent Breast Cancer in Women with Early Stage HER2-Positive Breast Cancer in a Large Community Health Plan

PURPOSE: Clinical outcomes have improved for women with early stage, HER2-positive breast cancer following the FDA approval of adjuvant trastuzumab use in 2006. However, only limited information exists on such patients’ outcomes in real-world settings outside of clinical trials. We examined the risk...

Descripción completa

Detalles Bibliográficos
Autores principales: Haque, Reina, Chen, Lie Hong, Oestreicher, Nina, Lalla, Deepa, Chlebowski, Rowan T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10440088/
https://www.ncbi.nlm.nih.gov/pubmed/37605715
http://dx.doi.org/10.2147/BCTT.S420061

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10440088/
https://www.ncbi.nlm.nih.gov/pubmed/37605715
http://dx.doi.org/10.2147/BCTT.S420061

Ejemplares similares